%0 Journal Article %A CARLA MINOIA %A NICOLA SGHERZA %A GIACOMO LOSETO %A GIUSEPPINA GRECO %A CATERINA BUQUICCHIO %A FRANCESCA MERCHIONNE %A CHANDRAKALA TOLDO %A IDA GALISE %A ANGELA MELPIGNANO %A GIUSEPPE TARANTINI %A VINCENZO PAVONE %A ATTILIO GUARINI %T Azacitidine in the Front-line Treatment of Therapy-related Myeloid Neoplasms: A Multicenter Case Series %D 2015 %J Anticancer Research %P 461-466 %V 35 %N 1 %X Background/Aim: A continued increase in the incidence of therapy-related myeloid neoplasms (t-MN) is expected due to the improvement of chemotherapeutic treatments for solid and haematological malignancies. The use of 5-azacytidine (AZA) is emerging in these patients. We, therefore, analyzed the outcome of patients with t-MN ineligible for intensive chemotherapy treated in the front-line with AZA. Patients and Methods: We retrospectively collected clinical data from consecutive patients with t-MN treated in the front-line with AZA at five Haematology Centers. Response to therapy, overall survival (OS) and safety were considered. Results: The overall response rate was of 35.7% with a median OS of 9.6 months. Patients who were heavily pre-treated for their primary malignancy (more than 3 lines of chemotherapy) presented a significant inferior OS (4.9 months). The principal reported toxicity was haematological with severe infections occurring in a minority of patients. Fatigue was the most common extra-haematological toxicity. Conclusion: New aspects emerged on the management of t-MN. AZA may represent a reasonable choice for patients ineligible for intensive treatment, with the exception of heavily pre-treated patients who presented –anyway- a worse outcome. %U https://ar.iiarjournals.org/content/anticanres/35/1/461.full.pdf